Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.
A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a p
The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza vaccine FluMist Quadrivalent which would allow it to be administered by patients
Moderna’s combined mRNA-based vaccine for COVID-19 and seasonal influenza has been shown to be at least as effective as jabs given separately in a phase 1/2 trial, setting
Researchers at the National Institutes of Health (NIH) have started dosing patients in a phase 1 trial of a new influenza vaccine candidate that aims to sidestep the annua
With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influ
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.